Solid Biosciences to Participate at the Truist Securities BioPharma Symposium
Solid Biosciences (Nasdaq: SLDB), a company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in an upcoming industry event.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB), a company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in an upcoming industry event. Chief Medical Officer Gabriel Brooks, M.D. will be part of a Genetic Medicine Panel at the Truist Securities BioPharma Symposium on November 7, 2024, at 1:45 p.m. ET in New York. Institutional investors can arrange meetings with management through their Truist representatives.
Details
News Market Reaction – SLDB
The recorded move for SLDB in the trading session of this news was -3.66%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHARLESTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Gabriel Brooks, M.D., Chief Medical Officer, will participate in a Genetic Medicine Panel at the Truist Securities BioPharma Symposium on Thursday, November 7, 2024, at 1:45 p.m. ET in New York.
Institutional investors interested in meeting with management during the conference may reach out to their Truist representatives.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.